Plasma levels of heparin cofactor II (HCII), thrombin-HCII complex (THC), antithrombin (AT), and thrombin-AT complex (TAT) were evaluated in patients with disseminated intravascular coagulation (DIC) associated with several underlying diseases. Plasma levels of AT were significantly reduced in almost all underlying diseases associated with DIC, but the plasma levels of HCII and HCII/AT ratio were significantly reduced only in patients with infections. While the plasma level of TAT was significantly increased in patients with all underlying diseases associated with DIC, the increase of THC was not significant. Plasma levels ofAT were significantly reduced in DIC and pre-DIC associated with almost all underlying diseases, but those of HCII were significantly reduced only in DIC and pre-DIC patients with inflammatory diseases. The plasma levels of TAT were significantly increased in DIC, pre-DIC, and non-DIC patients with Disseminated intravascular coagulation (DIC) (1,2) often occurs in patients with solid cancer, sepsis, and leukemia, and sometimes it is associated with a severe bleeding tendency and multiple organ failure. Plasma levels of antithrombin (AT) are significantly reduced in DIC especially that occurring in sepsis (3), and the outcome of septic patients with low AT level are reported to be poor (4). Because the plasma levels of thrombin-antithrombin complex (TAT) and D-dimer
all underlying diseases, and those of THC were significantly increased in DIC and pre-DIC patients with inflammatory diseases. The plasma levels of THC were not significantly increased in non-DIC patients of any disease group. The decrease of AT may be caused by thrombin generation or inflammatory reaction that occurs in DIC associated with underlying diseases, while the decrease of HCII might be caused by both thrombin generation and inflammatory reaction. Finally, AT inhibits thrombin more strongly than HCII in several underlying diseases associated with DIC except for inflammatory diseases. In inflammatory diseases, HCII might play an important role in preventing the onset of DIC. Key Words: Heparin cofactor II-Thrombinheparin cofactor II complex-DIC-Infection. are significantly increased in DIC (5, 6) , remarkable thrombin generation is believed to occur in DIC.
In addition to heparin, the main physiologic thrombin inhibitors are AT and heparin cofactor II (HCII). The deficiency of AT (7) or HCII (8) is associated with thrombosis. HCII (9), a plasma glycoprotein, is a member of the SERPIN family of proteinase inhibitors. HCII is relatively a specific inhibitor of thrombin and its activity is increased approximately 1000-fold in the presence of heparin. The activity of HCII is also increased in the presence of dermatan sulfate. Elevated plasma levels of thrombin-HCII complex (THC) were also reported in DIC (10) .
A large phase III clinical trial using plasma-derived AT failed to demonstrate a protective effect against thrombin (11) . A phase III study using activated protein C (APC), which was halted prematurely due to the statistical efficacy of APC, showed that APC reduced the relative risk of death by 19.4% (12) . A phase III trial with tissue factor pathway inhibitor for severe sepsis is currently in progress. The natural anticoagulants may exert not only antithrombotic but also antiinflammatory effect in sepsis.
In this study, the plasma levels of HCII and THC were measured in DIC patients associated with various diseases and they were compared with the plasma levels of AT and TAT.
MATERIALS AND METHODS
This study comprised 29 patients with DIC, 53 with pre-DIC, 83 with non-DIC, and 20 healthy volunteers. The patients had the following underlying diseases: 34 with infection; 25 with solid cancer (SG); 69 with hematopoietic tumor; 16 with burn, traumas or organ failure who were admitted to the intensive care unit (ICU); and 21 patients with other diseases (Table 1) . Patients admitted to the ICU had inflammatory diseases. The diagnosis of DIC was based on the criteria established by the Japanese Ministry of Health and Welfare (13, 14) . Pre-DIC, which does not fulfill DIC criteria, subsequently evolved to DIC. We defined pre-DIC as the condition at least 1 week before the onset of DIC (15) .
Plasma samples from all patients were drawn before DIC treatment. The activity of AT in plasma was measured by an amidolytic assay, using Berichrom antithrombin (Behringwerke AG, Marburg, Germany). The plasma level of TAT was determined by enzyme-linked immunosorbent assay (ELISA) using the TAT test kit (Kokusai-Shiyaku, Kobe, Japan). The plasma level of THC was measured by ELISA using an affinity purified sheep antibody to thrombin (Cedarlane, Ontario, Canada) as a capture antibody, and detection of HCII in THC was done using a peroxidase-conjugated, affmity purified goat antibody to HCII (Cedarlane, Ontario, Canada). Plasma level of HCII was measured by ELISA using a polyclonal affinity purified anti-HCII (Cedarlane, Ontario, Canada) as the capture antibody and peroxidase conjugated goat anti-HCII (Cedarlane, Ontario, Canada) as the detecting antibody.
Data were expressed as the mean + standard error. Statistical differences between healthy volunteers and each patient group were assessed by the Dunnett's nonparametric multiple comparison test (Steel's test). Linear regression analysis was performed by the least square method.
RESULTS
The plasma levels of AT were significantly lower in patients with infections, solid cancer, hematopoietic tumor, and in the ICU than in healthy volunteers (p < 0.01). The plasma levels of HCII were significantly reduced only in patients with infections (p < 0.01). The HCII/AT ratio was significantly lower only in patients with infection than in healthy volunteers (p < 0.01). The plasma levels of TAT were significantly higher in patients with all underlying diseases than in healthy volunteers (p < 0.01). The plasma levels of THC were markedly increased in patients with infection, solid cancer, and ICU, but they were not statistically significant ( Fig. 1 ). The THC/TAT ratio was significantly lower in patients with all underlying diseases than in healthy volunteers (p < 0.01) ( Table 2 ). The plasma levels of AT were significantly lower in patients with DIC, pre-DIC, or non-DIC than in healthy volunteers (p < 0.01). The plasma levels of HCII were significantly lower in patients with DIC or pre-DIC than in healthy volunteers (p < 0.05). There was no significant dif-ference in HCII/AT ratio among DIC, pre-DIC, non-DIC, and healthy volunteers. The plasma levels of TAT and THC were significantly higher in patients with DIC (p < 0.01), pre-DIC (p < 0.01), and non-DIC (p < 0.05) than in healthy volunteers. The THC/TAT ratio was significantly lower in patients with DIC, pre-DIC, and non-DIC than in healthy volunteers (p < 0.01) ( Table 3 ). The plasma levels of AT were significantly lower in DIC patients with all underlying diseases than in healthy volunteers (p < 0.01), but those of HCII were significantly lower only in DIC patients with infection (p < 0.01) or in the ICU (p < 0.05) than in healthy volunteers. The plasma levels of AT were significantly lower in pre-DIC patients with infection (p < 0.01), solid cancer (p < 0.01), hematopoietic tumor (p < 0.05), or in the ICU (p < 0.01) than in healthy volunteers. The plasma levels of HC-Il were significantly lower only in pre-DIC patients with infection (p < 0.01) and in the ICU (p < 0.01) than in healthy volunteers. In patients with infections, plasma levels of HCII were lower in DIC than in pre-DIC patients. The plasma levels of AT were significantly lower in non-DIC patients with infection (p < 0.01), solid cancer (p < 0.05), hematopoietic tumor (p < 0.01), or in the ICU (p < 0.01) than in healthy volunteers and those of HCII were significantly lower in non-DIC pa-tients with infection (p < 0.05) than in healthy volunteers ( Table 4 ).
The plasma levels of TAT were significantly higher in DIC patients with all underlying diseases (p < 0.01), and those of THC were significantly higher in DIC patients with infections, solid cancer, or in the ICU than in healthy volunteers (p < 0.01). The plasma levels of TAT were significantly higher in pre-DIC patients with all underlying diseases and those of THC were significantly higher in pre-DIC patients with solid cancer and in the ICU than in healthy volunteers. The plasma levels of TAT were significantly higher in non-DIC patients with all underlying diseases than in healthy volunteers. The plasma levels of THC were significantly lower in non-DIC patients with solid cancer and hematopoietic tumor than in healthy volunteers ( Table 5) .
Correlation between AT and HCII was low in all underlying diseases of DIC, but it was significantly high in DIC and pre-DIC (Table 6 ). There was no significant correlation between TAT and THC among various underlying diseases, DIC, pre-DIC, non-DIC, and healthy volunteers. 
DISCUSSION
The consumption of AT may lead a vicious circle by facilitating continuous intravascular fibrin formation, followed by ischemic tissue injury and accelerated activation of blood coagulation. Infusion of AT may exert an antiinflammatory effect by counteracting microvascular thrombosis (16) . Early and high-dose administration of AT to patients with severe blunt trauma appears to attenuate the posttraumatic inflammatory response or to significantly improve outcome (17) .
However, phase III trial with AT in severe sepsis was not effective (11) . The explanation for lack of effectiveness of AT is unknown but it is due to inappropriate choice of antithrombin dosage. The dose required for stimulation of prostacyclin synthesis is relatively high (18) .
The plasma levels of AT were significantly reduced in patients with infections, solid cancer, hematopoietic tumor, and in the ICU, but the plasma levels of HCII and HCII/AT ratio were significantly reduced only in infections. The plasma levels of TAT were significantly increased in patients with all underlying diseases, but those of THC were not statistically significant. The THC/TAT ratio was significantly reduced in all patients with underlying diseases. These findings suggest that AT is more consumed by thrombi in most underlying diseases with DIC than HCII. Except in infections, AT is a stronger inhibitor than HCII. Both AT and HCII are reduced in DIC except in acute promyelocytic leukemia (19) . Because HCII is significantly reduced only in infections and the increase of THC was not significant, HCII may be a spill-over from vessels. It is considered that HCII is primarily an extravascular inhibitor (20) .
In DIC and pre-DIC, the plasma levels of AT and HCII were significantly reduced and those of TAT and THC were significantly increased. There was no significant difference in HCII/AT ratio among DIC, pre-DIC, and non-DIC, suggesting that both AT and HCII are consumed by thrombin in DIC and pre-DIC. The plasma levels of HCII and THC may also be related with DIC as AT and TAT. The plasma levels of TAT were significantly high in DIC, pre-DIC, and non-DIC compared to those in healthy controls. However, the plasma levels of THC were significantly high in DIC and pre-DIC, but not in non-DIC. These findings suggest that TAT shows high sensitivity but low specificity for DIC and that THC shows high sensitivity and high specificity for DIC; that is, THC may be more useful for diagnosis of DIC than TAT.
The plasma levels of AT were significantly reduced in DIC and pre-DIC patients with almost all underlying diseases, but those of HCII were significantly reduced only in DIC and pre-DIC patients with inflammatory diseases (infections and ICU). In the present study, we found that the plasma levels of HCII are reduced and that DIC is progressive, suggesting that HCII might be a useful marker to predict outcome in severe sepsis. HCII might play an important role in inflammatory disorders with low AT. Replacement therapy of HCII may be theoretically useful for DIC in these states. In infections, not only AT but also HCII may work as thrombin inhibitor. The plasma AT levels were significantly reduced in non-DIC patients with almost all underlying diseases and those of HCII were significantly reduced in non-DIC patients with infections. The decrease of AT is caused by increased thrombin generation or by the inflammatory reaction, while that of HCII might be caused by both thrombin generation and inflammatory reaction.
The plasma levels of TAT were significantly increased in DIC, pre-DIC, and non-DIC patients with all underlying diseases, but those of THC were significantly increased in DIC patients with all underlying diseases and in pre-DIC patients with solid cancer and ICU, suggesting that AT is an inhibitor of thrombin in any condition, but HCII specifically acts in DIC or in some diseases with pre-DIC. The plasma levels of THC were not increased in non-DIC patients with all underlying diseases. These findings suggest that HCII might not be an important inhibitor of thrombin in non-DIC. HCII may play an important role in DIC or pre-DIC associated with inflammatory disorders.
